September 21, 2020
Dompé Appoints New Global Biotech Head
Ashley Kline, General Manager for Dompé U.S. to expand responsibilities as Global Biotech Head for Dompé Farmaceutici, S.p.A.
Dompé Farmaceutici S.p.A and Dompé U.S. Inc., (collectively Dompé) announced the promotion of Ashley Kline to Global Biotech Head for Dompé Farmaceutici, S.p.A., a role that she will hold in addition to her responsibilities as the General Manager for Dompé U.S., and Secretary of the Board of Directors of the U.S. affiliate. Kline will represent both Dompé U.S. and the Global Biotech business as part of the parent company’s leadership team.
Kline joined Dompé in July 2018 to build the U.S. organization and successfully commercialize Dompé’s first Biotech product in the US. Kline’s experience with biotech, ophthalmology and commercial operations began on the Lucentis team at Genentech, and she subsequently held more senior roles at Santen Inc and Adverum Biotech. Earlier in her career she was a consultant with Bain & Company in the firm’s San Francisco office. As Global Biotech Head, Kline will support the evolution of Dompé as a company and strengthen the growing Biotech business.
Dompé is a private, rapidly scaling global biopharmaceutical company founded in Milan, Italy. Today, Dompé employs more than 800 employees worldwide and reported annual revenue of 500 Million USD in 2019. The company maintains a U.S. commercial operations hub in the San Francisco Bay Area as well as an R&D presence in Boston. Over the past several years, Dompé has built on a successful primary care business and leveraged its global network in research and supercomputing capabilities to propel promising candidates for rare and underserved diseases to the clinic in four key therapeutic areas: ophthalmology, metabolic disorders, oncology, and pain management.